Why Osmotica Pharmaceuticals plc (Nasdaq: OSMT) stock dipped in the premarket?

In the premarket session, Osmotica Pharmaceuticals plc (Nasdaq: OSMT) sank -27.41% to $ 3.93 after The U.S. Food and Drug Administration has issued a Complete Response Letter regarding Osmotica Pharmaceutical’s NDA seeking approval of the investigational agent arbaclofen extended-release tablets to treat the spasticity resulting from multiple sclerosis.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

In its most recent NDA amendment, the Company failed to justify the change from the initial baseline to Day 84 in TNmAS-MAL scores between groups consisting of arbaclofen 40 mg and placebo. In its clinical review letter, the FDA proposed several changes to the product, including the requirement that the Company conducts new clinical studies to provide substantial evidence of arbaclofen’s efficacy.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Read More

Most Popular

Related posts